Drug Profile
Research programme: viral vaccines - Innogenetics
Alternative Names: ED 002; ED 009; EP 2220; EP 2230; GNI-103; GNI-105Latest Information Update: 24 Mar 2010
Price :
$50
*
At a glance
- Originator Genencor International; Pharmexa-Epimmune
- Developer Innogenetics; Pharmexa-Epimmune
- Class Papillomavirus vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hepatitis C; Human papillomavirus infections
Most Recent Events
- 28 May 2009 Pharmexa Epimmune has been acquired and merged into VaxOnco
- 09 Sep 2008 Innogenetics has been acquired by Solvay Pharmaceuticals
- 05 Sep 2007 Preclinical development of vaccine candidates ED 002 and ED 009 is ongoing